

9th MEETING OF THE INTERNATIONAL STUDY GROUP
FOR STEROID HORMONES

Rome, 5-7 December 1979

P R O G R A M M E

9th MEETING OF THE INTERNATIONAL STUDY GROUP
FOR STEROID HORMONES
Rome, 5-7 December 1979

PROGRAMME

WEDNESDAY -- December 5

09.00-09.20 Opening of the Meeting

BREAST CANCER

A.1. Endocrine Aspects of Etiology

09.20-09.45 1. R.D. BULBROOK: Endocrine determinants of risk of breast cancer

09.45-10.00 2. H. ADLERCREUTZ, B.R. GOLDIN, J.T. DWYER, J. WARREN and S.L. GORBACH:
Effect of diet on estrogen metabolism in women

10.00-10.10 Discussion

10.10-10.20 Interval

A.2. Hormone Receptors in Breast Cancer

10.30-10.55 3. W.L. MCGUIRE: Steroid receptors help to select treatment for breast
cancer patients10.55-11.10 4. T. THORSEN: Occupied and unoccupied oestradiol receptors in nuclei and
cytosol from human breast tumours11.10-11.25 5. A. MOLTENI, R. BAHU, E. FORS, M. MANGKORNKANOK and D. ALBERTSON:
Relationship of estradiol receptors to tissue and serum alpha-
lactalbumin and serum prolactin in human breast cancer

11.25-11.35 Discussion

A.3. Diagnostic and Prognostic Methods

11.35-12.00 6. E. ENGELSMAN: Diagnostic and prognostic methods

12.00-12.15 7. G. CONCOLINO, A. MAROCCHI, C. D'ATTOMA, G. RICCI, L. CARDILLO and
L. PICARDI: Receptor studies and survival in human breast cancer

12.15-12.25 Discussion

A.4. Endocrine Treatment of Breast Cancer

12.25-12.50 8. O. PEARSON: Endocrine treatment of breast cancer

12.50-13.05 9. G. TOLIS, A. CHAPDELAIN, K. ROBERTS, N. PAPANDREOU, M. PAPACHARALAMBOUS
and N. FRIEDMAN: Suppression of corpus luteum function by D-Leu⁶(des
Gly-NH₂¹⁰, Proethylamide⁹) GnRH in premenopausal women with breast cancer

13.05-13.15 Discussion

13.15-15.00 Interval

PROSTATE CANCER

A.5. Endocrine Aspects of Etiology

- 15.00-15.25 10. G.D. CHISHOLM and F.K. HABIB: Endocrine aspects of aetiology
- 15.25-15.50 11. F. SCIARRA, C. PIRO, V. TOSCANO, E. PETRANGELI, S. CAIOLA, F. DI SILVERIO, U. BRACCI and C. CONTI: Plasma testosterone (T), dihydrotestosterone (DHT), androstenedione (A), free testosterone fraction (FTF) and sex hormone binding globulin capacity (SHBG) in prostatic adenocarcinoma
- 15.50-16.00 Discussion

A.6. Hormone Receptors in Prostatic Cancer

- 16.00-16.25 12. N. BRUCHOVSKI and P.S. RENNIE: Hormone receptors in prostatic tissue
- 16.25-16.40 13. E. DAHLBERG, M. SNOCHOWSKI and J.-Å. GUSTAFSSON: Comparison between the contents of cytosolic steroid hormone receptors in the Dunning R-3327 prostatic adenocarcinoma of the rat and in human prostatic carcinoma
- 16.40-16.55 14. D.A.N. SIRETT, S.K. COWAN, A.E. JANECKO and J.K. GRANT: Distribution of dihydrotestosterone and of nuclear androgen receptors between stroma and epithelium of human benign hyperplastic prostatic tissue (BPH)
- 16.55-17.05 Discussion
- 17.05-17.25 Interval

A.7. Diagnostic and Prognostic Methods

- 17.25-17.50 15. F.H. SCHRÖDER: Diagnostic and prognostic methods
- 17.50-18.05 16. Å. POUSETTE, P. BJÖRK, K. CARLSTRÖM, B. FORSGREN, J.-Å. GUSTAFSSON and B. HÖGBERG: Purification and characterization of prostatic secretion protein (PSP), a major androgen-dependent protein in male accessory sexual glands in rat and man
- 18.05-18.20 17. P. VIHKO: Radioimmunoassay of human prostate-specific acid phosphatase in the diagnostic and follow-up of therapy of prostatic cancer
- 18.20-18.35 18. O.A. LEA and P.Å. HØISAETER: Diagnosis of prostate cancer using a radioimmunoassay for prostatic acid phosphatase in serum
- 18.35-18.45 Discussion

THURSDAY - December 6

A.8. Endocrine Treatment of Prostatic Disease

- 09.00-09.25 19. H. BECKER: Endocrine treatment of prostatic disease
- 09.25-09.40 20. A. STEG, G. BENOIT and A. LIMOUZIN-LAMOTTE: Percutaneous 17β -estradiol in the treatment of prostatic cancer
- 09.40-09.50 Discussion
- 09.50-10.30 General Discussion (Breast and Prostate Cancer)
- 10.30-10.50 Interval

OVARIAN FUNCTION AND DISEASE

B.9. Normal Ovarian Function

- 10.50-11.15 21. G.T. ROSS: Normal ovarian function
- 11.15-11.30 22. J.R.T. COUTTS, J.M. GAUKROGER, A.D.T. GOVAN and M.C. MACNAUGHTON:
Oestrogen synthesis by isolated human ovarian cells
- 11.30-11.45 23. K.D.R. SETCHELL and H. ADLERCREUTZ: The excretion of two new phenolic
compounds (Compound 180/442 and Compound 180/410) during the human
menstrual cycle and in pregnancy
- 11.45-11.55 Discussion
- 11.55-13.15 POSTER SESSION (Abstracts no. 39-63)

B.10 Mechanism of Ovulation

- 15.00-15.25 24. H.R. LINDNER: Mechanism of ovulation
- 15.25-15.40 25. P. KICOVIC, C. MASSAFRA, G. D'AMBROGIO and A.R. GENAZZANI: Induction of
ovulation in chronic anovulatory syndrome through a weak estrogen
supplementation
- 15.40-15.55 26. N.A. AL-HUSSARY and A.S. AL-JANABI: Oxytocin: a new effect, ovulation
induction
- 15.55-16.05 Discussion
- 16.05-16.30 Interval
- 16.30-19.00 GENERAL ASSEMBLY OF THE ASSOCIATION

FRIDAY — December 7

- 09.00-10.00 GENERAL DISCUSSION OF THE POSTERS
Moderator: H.J. VAN DER MOLEN
- 10.00-10.20 Interval
- B.11. Disturbances of the Menstrual Cycle
- 10.20-10.45 27. B. LUNENFELD: Disturbances of the menstrual cycle
- 10.45-11.00 28. A.R. GENAZZANI, G. D'AMBROGIO, C. MASSAFRA and P. KICOVIC: Effect of
epimestrol treatment on endocrine and clinical features of short and
inadequate luteal phase
- 11.00-11.15 29. M. ZACHMANN, B. MANELLA, L. SANTAMARIA, W. ANDLER and A. PRADER: Plasma
steroid response of pubertal girls to human menopausal gonadotropin
(HMG)
- 11.15-11.25 Discussion
- B.12. Hyperprolactinemia Syndrome
- 11.25-11.50 30. C. ROBYN: Hyperprolactinemia syndrome
- 11.50-12.05 31. A. CRAIG, R. FLEMING, W.P. BLACK, M.C. MACNAUGHTON, P. ENGLAND and
J.R.T. COUTTS: Infertility with normal menstrual rhythm : hormone
patterns before and during treatment with bromocriptine (CB 154)

- 12.05-12.20 32. P. FALASCHI, A. RÓCCO, P. POMPEI, F. SCIARRA and G. FRAJESE: Hyperprolactinaemia in polycystic ovary syndrome and in pituitary adenoma: prolactin response to pharmacological stimuli
- 12.20-12.35 33. D. FONZO, G. GALLONE, G.P. PAPINI, R. SIVIERI and F. CERESA: Discontinuous therapy with bromocriptine in hyperprolactinaemic patients with amenorrhea
- 12.35-12.30 34. P.M. KICOVIC, F. FRANCHI and M. LUISI: Failure of progesterone to enhance prolactin response to TRH in estrogen-primed ovariectomized women
- 12.50-13.00 Discussion
- 13.00-15.00 Interval
- B.13. Hirsutism as a Clinical Problem
- 15.00-15.25 35. P. MAUVAIS-JARVIS: Androgen secretion and skin metabolism in hirsutism
- 15.25-15.40 36. G. MAGRINI, F. MÉAN, P. BURCKHARDT, B. RUEDI and J.P. FELBER: Correlations between hirsutism, cycle disturbances and normal menstrual cycle stages with plasma androgen levels
- 15.40-15.50 Discussion
- B.14. Modern Diagnostic Methods for the Detection and Management of Ovarian Disease
- 15.50-16.15 37. G. LEYENDECKER: Modern diagnostic methods for the detection and management of ovarian disease
- 16.15-16.25 38. W.P. BLACK, R. FLEMING, M.C. MACNAUGHTON, A. CRAIG, P. ENGLAND and J.R.T. COUTTS: Infertility with normal menstrual rhythm - hormone profiles in response to HMG (pergonal) treatment
- 16.25-16.35 Discussion
- 16.35-17.30 General Discussion (Ovarian Function and Disease)
- 17.30-17.45 Closing of the Meeting

POSTERS

BREAST CANCER

39. G.P. GAIDANO, L. BERTA, E. ROVERO, P. ANSELMO, P. ROSATTI and C. NAVELLO: Significance of plasma sex hormone binding globulin (SHBG) binding capacity in breast cancer and fibro-cystic breast disease
40. D. VANDEKERCKHOVE, E. VANLUCHENE, W. AERTSENS and J. DE BOEVER: Neutral urinary steroids and estrogen receptors in breast cancer
41. L. BEEEX, A. KOENDERS, G. PIETERS, A. SMALS, J. HENDRIKX, Th. BENRAAD and P. KLOPPENBORG: Estradiol receptor activity (ER) in right or left sided breast cancer
42. J. DE BOEVER, K. DE GEEST, G. VAN MAELE and D. VANDEKERCKHOVE: Estrogen receptors in normal and malignant human breast tissues
43. H. TAKIKAWA, R. HORIUCHI, S. TANAKA and K. TARUSAWA: Immunofluorescent observation of prolactin receptors in cultured mammary carcinoma cells

PROSTATE CANCER

44. J.C. ROMIJN, G.J. v. STEENBRUGGE, K. OISHI, J. BOLT-DE-VRIES, W. HÖHN and F.H. SCHRÖDER: Characterization of a transplantable androgen-dependent human prostatic carcinoma (PC 82)
45. J.C. PLASSE, A. REVOL and B.P. LISBOA: In vitro metabolism of androgen by rat prostate
46. O.A. LEA and F.S. FRENCH: Characterization of androgen receptors in a rat prostate adenocarcinoma
47. P. KELLOKUMPU-LEHTINEN and R. SANTTI: Role of mesenchyme in the early cytodifferentiation of human prostate
48. S. RANNIKKO, A.-L. KAIRENTO, S.-L. KARONEN and H. ADLERCREUTZ: Prostatic carcinoma: correlation of hormonal pattern in plasma and urine to local extent of tumour, presence of metastases, grade of differentiation and primary response to hormonal treatment

OVARIAN FUNCTION AND DISEASE

49. G. FAMILIARI and P.M. MOTTA: Gap communicating junctions in theca interna cells of developing mouse follicles
50. P.M. MOTTA and S. MAKABE: Ovulation. A morphological analysis by scanning and transmission electron microscopy
51. J.S.G. BIGGS, S. MIKLOSI and F.J. THOMAS: Hormone production by the human corpus luteum in vitro: factors modifying tissue response in a perfusion system
52. D.H. BARLOW, R. FLEMING, M.C. MACNAUGHTON and J.R.T. COUTTS: Hormonal changes at female surgical castration
53. T. LEHTINEN, A.-L. KAIRENTO and H. ADLERCREUTZ: Monitoring of ovarian activity by the radioimmunological determination of estrogen glucuronides, estrone and estradiol in urine
54. A. MOLteni, E. FORS and J. LEESTMA: Sterility in Wobbler mice - a defect in cellular estradiol-binding activity
55. N. CARCEA, A. CARUSO, S. CAMPO and P. SICCARDI: Anatomico-functional evaluation of the ovary
56. E. MAININI and C. MAZZI: Oestrogen provocation test amplification of GnRH test in secondary amenorrhoea

57. R. FLEMING, A. CRAIG, D.H. BARLOW and J.R.T. COUTTS: The effects of mid-cycle transient hyperprolactinaemia, induced by metoclopramide (maxolon), on the menstrual cycle
58. F. FRAIOLI, V. LAVECCHIA, F. VITA, F. SANTORO, C. ORZI and L.R. MARCELLINO: Relationship between hormonal status and clinical response in human fibrocystic disease
59. A. VOLPE, C. BARBIERI, R. PELLATI, E. DELLA VECCHIA, A. GRASSO, G. MACCARONE and V. MAZZA: Endocrinological and therapeutic remarks of hyperprolactinaemic amenorrhoea
60. G. MAGRINI, F. MÉAN and J.P. FELBER: $20\alpha\text{OH}/17\alpha\text{OH}$ progesterone relationships with prolactin and androgens in normal, hyperprolactinemic and hirsute women
61. M. EGLOFF, N. SAVOURE, J. TARDIVEL-LACOMBE, C. MASSART, M. NICOL and H. DEGRELLE: Influence of SHBG on activity of 17β -hydroxysteroid oxidoreductase in human erythrocytes
62. M. MESSINA, P. BIFFIGNANDI, C. MANIERI, E. GHIGO and G.M. MOLINATTI: Spironolactone as an antiandrogen in the therapy of female hirsutism

Addendum to breast cancer section:

63. M. EDERY, J.C. SASSIER, J. GOUSSARD, L. DEHENNIN, R. SCHOLLER, J. REIFFSTECK and M.A. DROSDOWSKY: Endogenous estradiol- 17β concentration in breast tumours determined by mass fragmentography and by radioimmunoassay: relationship to receptor content